WebMD undergoes platform redesign

Share this article:
WebMD is conducting a root-and-branch redesign of its platform to allow for greater searchability, incorporation of new technologies like broadband video and new opportunities for advertisers. The revamped consumer site, set to launch later this month, will feature beefed-up search and symptom-check functions, greater personalization based on family health histories, more community features and 1,300 new broadcast-quality videos available through 60-some topical “health and wellness centers.” A redesigned professional site will go live later this year. Eighteen months in the making, it’s the first overhaul of WebMD’s infrastructure since the 1998 launch of the health portal, said president and CEO Wayne Gattinella. “This will enrich the user experience and enable us to incorporate next-generation 2.0 personalization and community applications that our older platform couldn’t support,” said Gattinella. The new platform will boost the site’s ranking in external searches, driving in more traffic, while the improved internal search function will allow advertisers to better segment the WebMD audience and fine-tune messaging based on search terms – for example, distinguishing between caretakers, newly-diagnosed patients and those already in treatment. In addition to advertising opportunities around the symptom-checker, WebMD will also offer preroll spots on its videos. The consumer site will offer a free Personal Health Record service, inviting users to store family health info in a secure, centralized place.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.